DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Glaucoma” report has been added to ResearchAndMarkets.com’s
This Market Spotlight report covers the Glaucoma market, comprising key
pipeline and marketed drugs, clinical trials, upcoming and regulatory
events, patent information, a 10-year disease prevalence forecast, and
licensing and acquisition deals, as well as presenting drug-specific
The author estimates that in 2017, there were 95.5 million prevalent
cases of glaucoma in adults aged 40 years and older worldwide, and
forecasts that number to increase to 113.4 million prevalent cases by
Africa is estimated to have the highest disease prevalence (4.79%),
while Europe and Oceania have the lowest prevalence (2.93% and 2.97%,
The majority of approved drugs in the glaucoma space target beta
adrenergic receptors or the prostaglandin F receptor. Zioptan and
Neptazane are the only marketed drugs for glaucoma administered via
the intraocular/subretinal/subconjunctival and oral routes,
respectively, with the remainder being topical formulations.
The majority of industry-sponsored drugs in active clinical
development for glaucoma are in Phase II, with only one drug in the
While a small number of mid-to-late-stage drugs in the glaucoma space
are exploring new targets, such as Rho kinase, the established target
prostaglandin F receptor continues to lead clinical development. The
largest number of drugs in mid-to-latestage development for glaucoma
are administered via the intraocular/subretinal/subconjunctival route,
with the remainder being topical and oral formulations.
High-impact upcoming events for drugs in the glaucoma space comprise
topline Phase II and Phase III trial results, an estimated PDUFA date,
an expected CHMP opinion, and expected CHMP supplemental filing
The overall likelihood of approval of a Phase I glaucoma asset is
3.9%, and the average probability a drug advances from Phase III is
58.3%. Drugs, on average, take 8.9 years from Phase I to approval,
compared to 8.8 years in the overall ophthalmology space.
There were 24 licensing and asset acquisition deals involving glaucoma
drugs during 2014-18. The largest deal was in 2014, when Merck sold
Asian rights for five of its glaucoma drugs to Santen for $600m.
The clinical trials distribution across Phase I-IV indicates that the
majority of trials for glaucoma have been in the late phases of
development, with 59% in Phase III-IV, and 41% in Phase I-II.
The US has a substantial lead in the number of glaucoma clinical
trials globally. Germany leads the major EU markets, while Japan has
the top spot in Asia.
Clinical trial activity in the glaucoma space is dominated by
completed trials. Novartis has the highest number of completed trials
for glaucoma, with 156 trials.
Novartis leads the industry sponsors with by far the highest number of
clinical trials for glaucoma, followed by Allergan.
Key Topics Covered:
RECENT EVENTS AND ANALYST OPINION
Bimatoprost Sustained Release for Glaucoma (January 7, 2019)
Bimatoprost Sustained Release for Glaucoma (June 13, 2018)
iDose-Travoprost for Glaucoma (January 10, 2018)
Rhopressa for Glaucoma (October 13, 2017)
Rhopressa for Glaucoma (October 11, 2017)
INO-8875 for Glaucoma (July 7, 2017)
Trabodenoson/Latanoprost FDC for Glaucoma (July 7, 2017)
KEY UPCOMING EVENTS
KEY REGULATORY EVENTS
Ocumension Gets Certain Asian Rights To NicOx’s Glaucoma Compound
Xelpros Approval Adds Spark To Sun’s Site Too?
PROBABILITY OF SUCCESS
LICENSING AND ASSET ACQUISITION DEALS
Astellas Buys UK Eye Gene Therapy Firm
Q BioMed, Washington Univ. Team Up In Glaucoma
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
For more information about this report visit https://www.researchandmarkets.com/r/nkassk
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900